These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22846983)

  • 1. Targeting hypertension in patients with cardiorenal metabolic syndrome.
    Rojas E; Velasco M; Bermúdez V; Israili Z; Bolli P
    Curr Hypertens Rep; 2012 Oct; 14(5):397-402. PubMed ID: 22846983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of chemical therapies for treating diabetic hypertension.
    Sarafidis PA; Alexandrou ME; Ruilope LM
    Expert Opin Pharmacother; 2017 Jun; 18(9):909-923. PubMed ID: 28480805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of angiotensin receptor blockers in diabetic nephropathy.
    Sharma AM; Weir MR
    Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotective effects of renin-angiotensin-aldosterone system blockers in type 2 diabetes: demystifying multiple treatment comparisons in a network meta-analysis.
    Catalá-López F
    Diabetologia; 2012 Sep; 55(9):2547-8; author reply 2549-50. PubMed ID: 22729654
    [No Abstract]   [Full Text] [Related]  

  • 7. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.
    Bakris GL
    Postgrad Med; 2003 May; 113(5):35-40, 43-4, 50. PubMed ID: 12764895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis.
    Cai J; Huang X; Zheng Z; Lin Q; Peng M; Shen D
    Nephrol Dial Transplant; 2018 Nov; 33(11):1968-1976. PubMed ID: 29579289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?
    Karagiannis A; Mikhailidis DP; Athyros VG; Kakafika AI; Tziomalos K; Liberopoulos EN; Florentin M; Elisaf M
    Expert Opin Ther Targets; 2007 Feb; 11(2):191-205. PubMed ID: 17227234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients.
    Isaacs AN; Vincent A
    J Clin Pharm Ther; 2016 Apr; 41(2):111-5. PubMed ID: 26850093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together?
    Verdecchia P; Angeli F; Mazzotta G; Ambrosio G; Reboldi G
    Curr Vasc Pharmacol; 2010 Nov; 8(6):742-6. PubMed ID: 20626343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.
    Reboldi G; Gentile G; Angeli F; Verdecchia P
    Vasc Health Risk Manag; 2009; 5(1):411-27. PubMed ID: 19475778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal protection with angiotensin receptor blockers: where do we stand.
    Schmieder RE; Ruilope LM; Barnett AH
    J Nephrol; 2011; 24(5):569-80. PubMed ID: 21404225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compelling drug indications in diabetic and nondiabetic nephropathy.
    Ritz E; Dikow R; Zeier M
    Curr Hypertens Rep; 2004 Aug; 6(4):293-9. PubMed ID: 15257864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.